知搜-全球专利检索

  1. Login
  2. Sign Up

Search Results

109 records (took 0.032 seconds)

    Advising diabetes treatments
    2.
    发明授权
    Advising diabetes treatments 有权

    公开(公告)号：US12002563B2

    公开(公告)日：2024-06-04

    申请号：US18182249

    申请日：2023-03-10

    Applicant: Aseko, Inc.

    Inventor： Robert C. Booth ,  John G. Clarke

    IPC: G16H20/17 ,  G16H50/30

    CPC classification number: G16H20/17 ,  G16H50/30

    Abstract: A method for managing glucose levels of a patient under the supervision of a healthcare professional (HCP). The method includes obtaining patient information for the patient, the patient information comprising patient medication data, patient monitoring data, and patient characteristic data. The method also includes creating a patient risk profile based on the patient information. The method also includes determining a likelihood that the patient will experience hyperglycemic effects based on the patient risk profile. The method also includes determining an optimum treatment plan for the patient based on the patient risk profile and the likelihood that the patient will experience hyperglycemic effects. The method also includes executing the optimum treatment plan.

    Advising Diabetes Treatments
    6.
    发明公开
    Advising Diabetes Treatments 审中-公开

    公开(公告)号：US20230290475A1

    公开(公告)日：2023-09-14

    申请号：US18182249

    申请日：2023-03-10

    Applicant: Aseko, Inc.

    Inventor： Robert C Booth ,  John G. Clarke

    IPC: G16H20/17 ,  G16H50/30

    CPC classification number: G16H20/17 ,  G16H50/30

    Abstract: A method for managing glucose levels of a patient under the supervision of a healthcare professional (HCP). The method includes obtaining patient information for the patient, the patient information comprising patient medication data, patient monitoring data, and patient characteristic data. The method also includes creating a patient risk profile based on the patient information. The method also includes determining a likelihood that the patient will experience hyperglycemic effects based on the patient risk profile. The method also includes determining an optimum treatment plan for the patient based on the patient risk profile and the likelihood that the patient will experience hyperglycemic effects. The method also includes executing the optimum treatment plan.

    System and Method for Optimizing Insulin Dosages for Diabetic Subjects
    7.
    发明申请
    System and Method for Optimizing Insulin Dosages for Diabetic Subjects 有权

    公开(公告)号：US20220074883A1

    公开(公告)日：2022-03-10

    申请号：US17474001

    申请日：2021-09-13

    Applicant: Aseko, Inc.

    Inventor： Robert C. Booth

    IPC: G01N27/327 ,  A61B5/145 ,  G16H40/63 ,  G16H40/67 ,  G16H10/60 ,  G16H20/17 ,  G16H10/40

    Abstract: A method and system for optimizing insulin dosages for diabetic subjects which includes a processor for calculating basal and bolus dosages to be recommended for meal types including breakfast, lunch, dinner, snack, or at miscellaneous times. The bolus calculations are specifically directed to time periods which are taken from either pre-meal, post-meal, bedtime, mid-sleep or miscellaneous times. The processor calculates an optimized bolus for a specific time period and meal type based upon prior basal dosages, prior glucose doses, hypoglycemia thresholds, mid-point of target ranges, and subject insulin sensitivity factors. A display is provided to the subject for sensing the optimized insulin dosage recommended at a specific time period and for a specific meal type.

    Diabetes management therapy advisor
    8.
    发明授权
    Diabetes management therapy advisor 有权

    公开(公告)号：US11200988B2

    公开(公告)日：2021-12-14

    申请号：US16503048

    申请日：2019-07-03

    Applicant: Aseko, Inc.

    Inventor： Robert C. Booth ,  Harry Hebblewhite

    IPC: G16H70/20 ,  G16H50/20 ,  G16H10/60 ,  G16H20/10 ,  G16H20/17 ,  G16H50/00

    Abstract: A method includes obtaining training data for a plurality of patients of a patient population. The training data includes training blood glucose history data including treatment doses of insulin administered by the patients of the patient population and one or more outcome attributes associated with each treatment dose. The method also includes identifying, for each patient of the patient population, one or more optimum treatment doses of insulin from the treatment doses yielding favorable outcome attributes. The method also includes receiving patient-state information for the treated patient, determining a next recommended treatment dose of insulin for the treated patient based on one or more of the identified optimum treatment doses associated with the patients of the patient population having training patient-state information similar to the patient-state information for the treated patient, and transmitting the next recommended treatment dose to a portable device associated with the treated patient.

    Insulin management
    9.
    发明授权
    Insulin management 有权

    公开(公告)号：US10535426B2

    公开(公告)日：2020-01-14

    申请号：US16273926

    申请日：2019-02-12

    Applicant: Aseko, Inc.

    Inventor： Robert C. Booth ,  Harry Hebblewhite

    IPC: G16H20/60 ,  A61M5/172 ,  A61B5/145 ,  A61B5/00 ,  A61M5/14 ,  G06F19/00 ,  G16H20/17 ,  G16H40/67 ,  G16H80/00 ,  G16H10/40 ,  A61M5/142

    Abstract: A method of administering insulin includes receiving blood glucose measurements of a patient at a data processing device from a glucometer. The blood glucose measurements are separated by a time interval. The method also includes receiving patient information at the data processing device and selecting a subcutaneous insulin treatment from a collection of subcutaneous insulin treatments. The selection is based on the blood glucose measurements and the patient information. The selection includes one or more of a subcutaneous standard program, a subcutaneous program without meal boluses, a meal-by-meal subcutaneous program without carbohydrate counting, a meal-by-meal subcutaneous program with carbohydrate counting, and a subcutaneous program for non-diabetic patients. The method also includes executing, using the data processing device, the selected subcutaneous insulin treatment.

Patent Agency Ranking